UK seizes illegal medicines and devices worth over £84m in last 15 years

As per WHO, about one in ten medical products in low-income and middle-income countries is substandard or falsified.

Phalguni Deswal November 01 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) celebrated 15 years since the launch of Operation Pangea by providing UK statistics from the programme.

The news of counterfeit Ozempic (semaglutide) pens has raised alarms over the last few months with the manufacturer, Novo Nordisk, and multiple countries reporting the harms of these products along with highlighting the differences in the packaging of the fake products, compared to the original.

Operation Pangea is coordinated by Interpol with support from multiple global organisations including the World Customs Organization, the World Health Organization (WHO), the United Nations Office on Drugs and Crime, the International Narcotics Control Board, and national health regulatory agencies.

The agency stated that the MHRA’s Criminal Enforcement Unit (CEU) has seized over 25 million illegally traded medicines and devices in the UK, which are valued at more than £84m ($101.9m) in the past 15 years. Furthermore, the agency seized illegal medicines worth £5m in 2023.

Operation Pangea XVI, which ran from 3-10 October, led to the seizure of medications worth $7m, as per Interpol. Most seized medications globally were erectile dysfunction medications. The biggest medical device seizure was the confiscation of approximately 11,000 Covid-19 irregular test kits in Australia.

Counterfeit Covid-19 medical devices have been an ongoing issue before, with the previous iteration of Operation Pangea (Operation Pangea XIII) seizing some 37,000 counterfeit medical devices in 2021. As per WHO, approximately one in ten medical products in low-income and middle-income countries is substandard or falsified.

There has been a 35% drop in the Covid-19 nucleic acid amplification tests (NAATs) market value in the US, as per GlobalData’s Covid-19 tests market model.

GlobalData is the parent company of Pharmaceutical Technology.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close